Carboplatin plus taxol is an effective third-line regimen in recurrent undifferentiated nasopharyngeal carcinoma.

PubWeight™: 0.78‹?›

🔗 View Article (PMID 12400975)

Published in Tumori on October 28, 2002

Authors

Mario Airoldi1, Fulvia Pedani, Sara Marchionatti, Anna Maria Gabriele, Giovanni Succo, Pietro Gabriele, Cesare Bumma

Author Affiliations

1: Department of Medical Oncology, San Giovanni Antica Sede Hospital, Turin, Italy. mario.airoldi@jumpy.it

Articles by these authors

Does tumor growth follow a "universal law"? J Theor Biol (2003) 2.47

Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst (2011) 2.47

Pancreatic resections after chemoradiotherapy for locally advanced ductal adenocarcinoma: analysis of perioperative outcome and survival. Ann Surg Oncol (2006) 1.45

A new training approach in endoscopic percutaneous tracheostomy using a simulation model based on biological tissue. Minerva Anestesiol (2015) 1.44

Subtotal laryngectomy with tracheohyoidopexy: a possible alternative to total laryngectomy. Laryngoscope (2006) 1.25

Endorectal magnetic resonance imaging at 1.5 Tesla to assess local recurrence following radical prostatectomy using T2-weighted and contrast-enhanced imaging. Eur Radiol (2008) 1.20

Induction gemcitabine and oxaliplatin therapy followed by a twice-weekly infusion of gemcitabine and concurrent external-beam radiation for neoadjuvant treatment of locally advanced pancreatic cancer: a single institutional experience. Cancer (2012) 1.18

Emptying the rectum before treatment delivery limits the variations of rectal dose - volume parameters during 3DCRT of prostate cancer. Radiother Oncol (2006) 1.08

Quality indicators in radiotherapy. Radiother Oncol (2007) 1.08

Clinical and dosimetric predictors of late rectal toxicity after conformal radiation for localized prostate cancer: results of a large multicenter observational study. Radiother Oncol (2009) 1.06

Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer (2003) 1.04

Accelerated versus conventional fractionated postoperative radiotherapy for advanced head and neck cancer: results of a multicenter Phase III study. Int J Radiat Oncol Biol Phys (2005) 0.98

Hyperthermia inhibits angiogenesis by a plasminogen activator inhibitor 1-dependent mechanism. Cancer Res (2003) 0.96

Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. J Clin Oncol (2002) 0.92

Induction chemotherapy with carboplatin and taxol followed by radiotherapy and concurrent weekly carboplatin + taxol in locally advanced nasopharyngeal carcinoma. Cancer Chemother Pharmacol (2010) 0.90

Accessibility as a major determinant of radiotherapy underutilization: a population based study. Health Policy (2006) 0.90

Induction chemotherapy with cisplatin and epirubicin followed by radiotherapy and concurrent cisplatin in locally advanced nasopharyngeal carcinoma observed in a non-endemic population. Radiother Oncol (2009) 0.89

Surgery and radiotherapy in the treatment of malignant parotid tumors: a retrospective multicenter study. Tumori (2009) 0.88

Docetaxel and vinorelbine: an effective regimen in recurrent squamous cell esophageal carcinoma. Med Oncol (2003) 0.88

Cytoreductive surgery and intraperitoneal chemohyperthermia for recurrent peritoneal carcinomatosis from ovarian cancer. World J Surg (2004) 0.87

Is it time to tailor the prediction of radio-induced toxicity in prostate cancer patients? Building the first set of nomograms for late rectal syndrome. Int J Radiat Oncol Biol Phys (2011) 0.87

Laparotomy wound recurrence of endometrial carcinoma. Gynecol Oncol (2003) 0.87

Postoperative adjuvant chemoradiotherapy in older patients with head and neck cancer. Arch Otolaryngol Head Neck Surg (2004) 0.85

Clinical and biological prognostic factors in 179 cases with sinonasal carcinoma treated in the Italian Piedmont region. Oncology (2009) 0.85

Chondrosarcoma of the nasal septum. Eur Arch Otorhinolaryngol (2014) 0.84

External beam radiotherapy plus high-dose-rate brachytherapy for treatment of locally advanced prostate cancer: the initial experience of the Catalan Institute of Oncology. Brachytherapy (2009) 0.83

Increasing the risk of late rectal bleeding after high-dose radiotherapy for prostate cancer: the case of previous abdominal surgery. Results from a prospective trial. Radiother Oncol (2012) 0.83

Impact of the radiotherapy technique on the correlation between dose-volume histograms of the bladder wall defined on MRI imaging and dose-volume/surface histograms in prostate cancer patients. Phys Med Biol (2013) 0.82

Well and intermediate differentiated laryngeal chondrosarcoma: toward conservative surgery? Eur Arch Otorhinolaryngol (2013) 0.82

Non-human immunodeficiency virus-related Kaposi's sarcoma of the oropharynx: a case report and review of the literature. J Med Case Rep (2013) 0.82

Clinical and technical feasibility of ultra-boost irradiation in Dominant Intraprostatic Lesion by Tomotherapy: preliminary experience and revision of literature. Panminerva Med (2015) 0.81

Prospective phase II trial of neoadjuvant chemo-radiotherapy with Oxaliplatin and Capecitabine in locally advanced rectal cancer (XELOXART). Med Oncol (2013) 0.81

Swallowing, voice, and quality of life after supratracheal laryngectomy: preliminary long-term results. Head Neck (2014) 0.81

Quality assurance of a record-and-verify system. Tumori (2009) 0.80

Increased overall survival independent of RECIST response in metastatic breast cancer patients continuing trastuzumab treatment: evidence from a retrospective study. Breast Cancer Res Treat (2011) 0.80

Pharmacokinetic study of oxaliplatin iv chronomodulated infusion combined with 5-fluorouracil iv continuous infusion in the treatment of advanced colorectal cancer. Farmaco (2003) 0.79

Docetaxel, carboplatin and concomitant radiotherapy for unresectable squamous cell carcinoma of the head and neck: pharmacokinetic and clinical data of a phase I-II study. Am J Clin Oncol (2004) 0.79

Irradiation of pacemakers and cardio-defibrillators in patients submitted to radiotherapy: a clinical experience. Tumori (2010) 0.79

Docetaxel and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Am J Clin Oncol (2003) 0.79

Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy. Tumori (2012) 0.78

Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer. Acta Oncol (2003) 0.78

Prostate image-guided radiotherapy by megavolt cone-beam CT. Strahlenther Onkol (2011) 0.78

Paclitaxel and carboplatin in neo-adjuvant and concomitant chemoradiotherapy in locally advanced head and neck squamous cell carcinoma. Tumori (2003) 0.78

Dose to organs at risk in the upper abdomen in patients treated with extended fields by helical tomotherapy: a dosimetric and clinical preliminary study. Radiat Oncol (2013) 0.77

Changes in patterns of practice for prostate cancer radiotherapy in Italy 1995-2003. A survey of the Prostate Cancer Study Group of the Italian Radiation Oncology Society. Tumori (2014) 0.77

Quality assurance of 3D-CRT: indications and difficulties in their applications. Crit Rev Oncol Hematol (2008) 0.77

Paclitaxel and pegylated liposomal doxorubicin in recurrent head and neck cancer: clinical and unexpected pharmacokinetic interactions. Anticancer Res (2008) 0.77

Radiotherapy after partial laryngectomy: an analysis of 36 cases and a proposal to optimize radiotherapy. Tumori (2009) 0.77

Clinical application and dosimetric calibration procedure of the superficial and orthovoltage therapy unit Therapax DXT300. Tumori (2002) 0.77

Salvage external beam radiotherapy for recurrent prostate adenocarcinoma after high-intensity focused ultrasound as primary treatment. Urol Int (2013) 0.77

Gemcitabine and vinorelbine in recurrent head and neck cancer: pharmacokinetic and clinical results. Anticancer Res (2003) 0.76

Comparison of endorectal magnetic resonance imaging, clinical prognostic factors and nomograms in the local staging of prostate cancer patients treated with radiotherapy. Tumori (2008) 0.76

Cisplatin+Vinorelbine Treatment of Recurrent or Metastatic Salivary Gland Malignancies (RMSGM): A Final Report on 60 Cases. Am J Clin Oncol (2017) 0.76

Gemcitabine and oxaliplatin in patients with pancreatic adenocarcinoma: clinical and pharmacokinetic data. Pancreas (2006) 0.76

External beam radiotherapy with dose escalation in 1080 prostate cancer patients: definitive outcome and dose impact. Panminerva Med (2016) 0.75

Percentage of positive prostate biopsies independently predicts biochemical outcome following radiation therapy for prostate cancer. Panminerva Med (2015) 0.75

Radiotherapy alone or with concomitant daily low-dose carboplatin in locally advanced, unresectable head and neck cancer: definitive results of a phase III study with a follow-up period of up to ten years. Tumori (2010) 0.75

Technical and clinical description of a case of extensive anogenital Paget's disease associated with anal cancer treated by tomotherapy. Tumori (2014) 0.75

Italian survey in postoperative radiation therapy for prostate carcinoma by the AIRO National Working Group on Prostate Radiotherapy: definitive results. Tumori (2005) 0.75

Hereditary paraganglioma syndrome associated with SDHD gene mutations: a patient with multicentric presentation treated with radiotherapy. Case report. Tumori (2011) 0.75

Gemcitabine and oxaliplatin in patients with metastatic breast cancer resistant to or pretreated with both anthracyclines and taxanes: clinical and pharmacokinetic data. Am J Clin Oncol (2006) 0.75

Radiotherapy after surgery for advanced adenoid cystic carcinoma of paranasal sinus. Lancet Oncol (2005) 0.75